Brief: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data
02/06/2025 23:03
June 2 (Reuters) - Kyowa Kirin Co Ltd 4151.T: KURA ONCOLOGY INC: FDA PDUFA TARGET ACTION DATE OF NOVEMBER 30 FOR ZIFTOMENIB Source text: ID:nGNXc1FygT Further company coverage: 4151.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia